Leucine-Rich Alpha 2 Glycoprotein-1

Athens Research

Leucine-Rich Alpha 2 Glycoprotein-1

9

Infection, Inflammation, Cancer, Cardiovascular Disease, Autoimmune Diseases, Parkinson's, Biotherapeutics, In Vitro Diagnostics

Research Use Only

≥95% by SDS-PAGE. Positive reaction to anti-LRG1 on Western Blot.

Leucine-rich alpha-2-glycoprotein

Leucine-rich alpha-2 glycoprotein 1 (LRG1) is a multifunctional plasma protein present at concentrations of 21–50 ug/mL in healthy individuals. As an acute-phase protein, LRG1 levels rise significantly during bacterial infections and various inflammatory conditions, but its regulation is independent of traditional markers like C-reactive protein (CRP). LRG1 plays a key role in modulating immune and vascular responses, acting as an upstream regulator of the TGF-bèta signaling pathway and promoting angiogenesis by influencing endothelial cell behavior. It binds cytochrome c, a molecule involved in apoptosis, thereby potentially supporting cell survival during tissue injury and inflammation. Elevated LRG1 is recognized as a biomarker for multiple cancers-including non-small cell lung, colorectal, pancreatic, and ovarian cancer-where it correlates with disease progression and prognosis. Beyond oncology, LRG1 is implicated in cardiovascular, renal, autoimmune, and neurodegenerative diseases, such as Parkinson’s disease, and is being explored as a diagnostic and therapeutic target due to its roles in inflammation, vascular dysfunction, and tissue remodeling.

more then 1 year

Prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests.

≤ -20°C

12352202